<DOC>
	<DOCNO>NCT00078377</DOCNO>
	<brief_summary>The primary objective study determine whether treatment Armodafinil ( CEP-10953 ) effective placebo treatment patient excessive sleepiness associate narcolepsy measure mean sleep latency Maintenance Wakefulness Test ( MWT ) ( 20-minute version ) ( average 4 naps 0900 , 1100 , 1300 , 1500 ) Clinical Global Impressions Change ( CGI-C ) rating ( related general condition ) week 12 ( last postbaseline observation )</brief_summary>
	<brief_title>Safety Efficacy Study Armodafinil ( CEP-10953 ) Treatment Excessive Sleepiness Associated With Narcolepsy</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Diagnosis Criteria Inclusion : Patients include study follow criterion meet : Written inform consent obtain The patient outpatient , man woman ethnic origin , 18 65 year age ( inclusive ) The patient complaint excessive sleepiness The patient current diagnosis narcolepsy accord ICSD criterion . The patient good health determine medical psychiatric history , physical examination , electrocardiogram ( ECG ) , serum chemistry , hematology , urinalysis . Women must surgically sterile , 2 year postmenopausal , , childbearing potential , use medically accept method birth control ( ie , barrier method spermicide , steroidal contraceptive [ oral , implanted , DepoProvera contraceptives must use conjunction barrier method ] , intrauterine device [ IUD ] ) agree continue use method duration study . The patient mean sleep latency 6 minute less determined Multiple Sleep Latency Test ( MSLT ) ( performed 0900 , 1100 , 1300 , 1500 ) . The patient CGIS ( Clinical Global Impression Severity Illness ) rating 4 . The patient medical psychiatric disorder could account excessive daytime sleepiness . The patient able complete self rating scale computerbased test . The patient willing able comply study restriction attend regularly schedule clinic visit specify protocol . Criteria Exclusion : Patients exclude participate study 1 follow criterion meet . The patient : clinically significant , uncontrolled medical psychiatric condition ( treat untreated ) probable diagnosis current sleep disorder narcolepsy consume caffeine include coffee , tea and/or caffeine contain beverage food average 600 mg caffeine per day use prescription drug disallow protocol clinically significant use thecounter ( OTC ) drug within 7 day second screening visit history alcohol , narcotic , drug abuse define Diagnostic Statistical Manual Mental Disorders American Psychiatric Association , 4th Edition ( DSM IV ) positive UDS screen visit , without medical explanation clinically significant deviation normal physical examination pregnant lactate woman . ( Any woman become pregnant study withdrawn study . ) use investigational drug within 1 month screen visit disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) know clinically significant drug sensitivity stimulant modafinil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Narcolepsy</keyword>
	<keyword>Excessive Sleepiness</keyword>
	<keyword>Cataplexy</keyword>
	<keyword>Sleep Attacks</keyword>
	<keyword>Excessive Sleepiness associate Narcolepsy</keyword>
	<keyword>Cephalon</keyword>
	<keyword>Cephalon , Inc</keyword>
	<keyword>Nuvigil</keyword>
</DOC>